NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$495.00
Cat. #: 26184 |
Gene Symbol: BRAF, BRAF1, RAFB1 |
Description: Anti-BRaf(V600D) Mouse Monoclonal Antibody |
Background: B-Raf is a member of the Raf family of Ser/Thr protein kinases. It functions downstream of Ras to regulate the MAP kinase signaling pathway. Mutations in the BRAF gene cause diseases. Inherited mutations in BRAF cause cardiofaciocutaneous syndrome. Acquired mutations in BRAF have been found in cancers. |
Immunogen: A synthetic peptide from the internal region of BRaf(V600D), human origin. |
Applications: ELISA, WB, IF, IHC |
Recommended Dilutions: ELISA 1:1000-1:5000 WB 1:500-1:2000 IF 1:100-1:200 IHC 1:100-1:200 |
Concentration: 0.5 mg/ml |
Host Species: Mouse |
Format: Liquid |
Clonality: Monoclonal |
Isotype: IgG |
Purity: Purified from ascites |
Preservative: No |
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol |
Species Reactivity: Recognizes B-Raf V600D, but not wild type B-Raf proteins from vertebrates. |
Storage Conditions: Store at -20°C. Avoid repeated freezing and thawing |
1. Potential Utility of Mutant Oncogene-Specific Antibodies in Melanoma Am J Dermatopathol. 2014 |